(Q46560177)

English

Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines

scientific article published in September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

6

object named as

Helena Käyhty

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

author name string

Maija Toropainen

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Leena Saarinen

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Elisabeth Wedege

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Karin Bolstad

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

P Helena Mäkelä

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

23

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

40

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

4821-4833

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Cross-reacting serum opsonins to meningococci after vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci1Presented in part at The Tenth International Pathogenic Neisseria Conference, Baltimore, MD, USA, September 8–13, 1996.1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Experimental meningococcal meningitis in the infant rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

The opcA and (psi)opcB regions in Neisseria: genes, pseudogenes, deletions, insertion elements and DNA islands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Highly ConservedNeisseria meningitidisInner‐Core Lipopolysaccharide Epitope Confers Protection against Experimental Meningococcal Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Candidate Neisseria meningitidis NspA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.05.005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15970361

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46560177&oldid=2163777025"